Enlivex Ltd. (ENLV)
| Market Cap | 167.96M +577.3% |
| Revenue (ttm) | n/a |
| Net Income | 1.24B |
| EPS | 25.48 |
| Shares Out | 241.05M |
| PE Ratio | 0.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,914 |
| Open | 0.7300 |
| Previous Close | 0.7206 |
| Day's Range | 0.6902 - 0.7399 |
| 52-Week Range | 0.6600 - 2.1000 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+2,770.26%) |
| Earnings Date | Jun 15, 2026 |
About ENLV
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for ENLV stock is "Strong Buy" and the 12-month stock price target is $20.0.
News
Enlivex Therapeutics doses first patient in Allocetra trial
Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related…
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd...
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that ...
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
New acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” ...
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced tha...
Enlivex Therapeutics files to sell 23.33M ordinary shares for holders
16:19 EDT Enlivex Therapeutics (ENLV) files to sell 23.33M ordinary shares for holders
Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra
Enlivex announced that it has received Clinical Trial Application, CTA, approval by the Danish Medicines Agency, DKMA, for the Phase 2b trial of Allocetra, the Company’s clinical-stage immunotherapy, ...
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Nes-Ziona, Israel, April 21, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company, today announced that it has received Clinical Trial Applica...
Ondo Global Markets Tokenizes Enlivex's Ordinary Shares
Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced tha...
Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Enlivex Therapeutics (ENLV) to $20 from $13 and keeps a Buy rating on the shares. The company’s debt financing…
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers ...
Enlivex Earnings Call Transcript: Q4 2025
2025 saw record net income and EPS, driven by treasury gains from prediction markets, especially RAIN tokens. Clinical progress continued with FDA clearance for a Phase IIb osteoarthritis trial, while new financing and share repurchase initiatives support future growth.
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financi...
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor The Comp...
Enlivex Therapeutics announces FDA clearance of Allocetra new drug application
Enlivex announced that the FDA has cleared its investigational new drug application for Allocetra, the company’s clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age...
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex's first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation ...
Enlivex Therapeutics management to meet virtually with BTIG
Virtual Meeting to be held on February 23-26 hosted by BTIG.
Enlivex Therapeutics announces new listing of RAIN token on Kraken
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the ...
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics L...
Enlivex Therapeutics announces listing of RAIN token on WhiteBIT
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, expanding access to the token across...
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Listing expected to expand market access and secondary liquidity for Enlivex's primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: EN...
Enlivex Therapeutics shares to trade exclusively on Nasdaq
Enlivex Therapeutics (ENLV) announced that it has initiated a process to voluntarily delist its ordinary shares, par value NIS 0.40 per share, from the Tel Aviv Stock Exchange. Published first…
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing
Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Enlivex Therapeutics (ENLV) to $13 from $7 and keeps a Buy rating on the shares. The cites the company’s entry into the…